Loki Therapeutics – AWAKE™ Platform Technology

Chris Bradley, CEO of Loki Therapeutics discusses Loki’s proprietary AWAKE™ strategy that completely bypasses the major challenges faced by traditional immunotherapy approaches.  AWAKE reactivates and redirects pre-existing, life-long Memory T-cells created during childhood vaccination to target and eliminate cancer cells rather than training naïve T-cells against tumor antigens like traditional immunotherapy.

Read More

Graves’ Disease Awareness

Dr. Gary Lelli, Vice-Chair of Ophthalmology at Weill Cornell Medicine, discusses the Horizon Therapeutics and Prevent Blindness launch of FOCUS, an initiative created to help those living with Graves’ Disease recognize the symptoms of a separate, but related disease called Thyroid Eye Disease (TED), a serious, progressive and vision-threatening rare autoimmune disease that, in rare cases, can lead to blindness.

Read More

Cancer Screening Emergency During COVID-19 Pandemic

Dr. Lisa Ravindra, Primary Care Physician and Physician lead for Virtual Care Programs at Rush University Medical Center, discusses the dramatic dip in U.S. cancer screening, due mostly to people staying away from the doctor’s office because of COVID-19.  She talks about new guidelines published by The National Colorectal Cancer Roundtable and the important role that telehealth and at-home screening tests can play in detecting colorectal cancer earlier amidst this new normal. Learn more at Cologuard.

Read More

LLS Children’s Initiative and PedAL Trial

Returning guest, Dr. Gwen Nichols, Chief Medical Officer at the Leukemia & Lymphoma Society (LLS) discusses the Children’s Initiative, a $100M dollar effort to address the lack of treatments for pediatric blood cancers.  She also talks about the PedAL trial that is part of the Children’s Initiative. This master clinical trial will test simultaneously multiple targeted therapies for children who experience a relapse of their acute leukemia.   The study will take place at more than 200 sites worldwide that are part of the NCI-supported Children’s Oncology Group (COG) network of children’s hospitals, including those in the U.S., Australia, New Zealand, and Canada. 

Read More

Medtronic – Remote Monitoring Devices

Clinician safety is the top priority during the COVID-19 crisis. Ariel MacTavish, VP/GM of Respiratory Interventions in the MITG division and  Frank Chan, VP/GM of Patient Monitoring at Medtronic discuss Medtronic’s first-of-its-kind software solution that enables doctors and nurses to manage and adjust ventilators remotely.  This reduces room entries and exposure and conserves PPE.  In addition, Medtronic is taking the lead to protect healthcare workers and prepare them for the potential next wave of COVID-19 by partnering with hospitals like Regions Hospital in St. Paul, Minn., where healthcare providers have access to a range of remote monitoring devices such as remote-access solutions for pulse oximeters, used to measure oxygen levels in the blood, and the latest in capnography to monitor carbon dioxide levels in the airways.

Read More

Muscle Mass – The Immune System

Recent research suggests that the loss of muscle mass is associated with compromised immunity and infections.  Dr. Suzette Pereira, Ph.D., a muscle health researcher and scientist, discusses how muscle mass can impact health status and outcomes, especially amongst older, high-risk, and chronically ill patients.  She talks about the type of lifestyle changes that can be made to maintain or improve muscle mass to help strengthen the immune system, and supplements that healthcare providers can recommend when seniors can’t get the nutrition they need to support muscle growth from diet alone. 

Read More

Caris Life Sciences partnering with Merus to detect neuregulin 1 (NRG1) fusions in cancer patients

Returning guest, Dr. David Spetzler, President and Chief Scientific Officer at Caris® Life Sciences discusses partnering with Merus, a clinical-stage oncology company, to detect neuregulin 1 (NRG1) fusions in cancer patients using Caris’ whole exome and whole transcriptome sequencing. The goal of this collaboration is to use Caris’ extensive suite of breakthrough next-generation sequencing technology to identify patients who may be eligible for Merus’ bispecific antibody Zenocutuzumab (“Zeno”) Phase 1/2 eNRGy trial and Early Access Program.

Read More